The relevant targets of anti-oxidative stress: a review

References

• Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11(3):298–300.
   PubMedGoogle Scholar
• Bsoul SA, Terezhalmy GT. Vitamin C in health and disease. J Contemp Dent Pract. 2004;5(2):1–13.
   PubMedGoogle Scholar
• Jacob RA, Sotoudeh G. Vitamin C function and status in chronic disease. Nutr Clin Care. 2002;5(2):66–74.
   PubMedGoogle Scholar
• Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med. 1992;13(1):55–74.
   PubMed Web of Science ®Google Scholar
• Xiao YM, Zhang SS, Tan ZH, et al. Toxicological damage of antioxidant vitamin E and its metabolites. China Oils Fats. 2004;29(11):46–48.
   Google Scholar
• Ishwarlal J, Sridevi D. High-dosage vitamin E supplementation and all-cause mortality. Anna Intern Med. 2005;143(2):156–158.
   Google Scholar
• Johnson WD, Morrissey RL, Usborne AL, et al. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol. 2011;49(12):3319–3327.
   PubMed Web of Science ®Google Scholar
• Zhao KS. Biological characteristics and effects of resveratrol. Chin J Pathophysiol. 2012;28(09):1709–1711 + 1717.
   Google Scholar
• Shi LL, Han C, Zhao JP, et al. Study on toxicological safety evaluation of astaxanthin. Food Nutr China. 2019;25(01):31–35.
   Google Scholar
• Wu LJ, Guo XM. Effects of astaxanthin and exercise on antioxidant capacity, blood lactic acid and uric acid metabolism in human body. China Sport Sci. 2017;37(01):62–67 + 80.
   Google Scholar
• Sahebkar A, Serban C, Ursoniu S, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55.
   PubMed Web of Science ®Google Scholar
• Ursoniu S, Sahebkar A, Serban MC, et al. Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci. 2015;11(2):253–266.
   PubMed Web of Science ®Google Scholar
• Sun CP, Tian WY. Astaxanthin - the red miracle sweeping the world. Beijing: China Medical Science Press; 2015.
   Google Scholar
• Hayes JD, McMahon M, Chowdhry S, et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–1748.
   PubMed Web of Science ®Google Scholar
• Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A. 1994;91(21):9926–9930.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Katsuoka F, Funayama R, et al. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 2012;40(20):10228–10239.
   PubMed Web of Science ®Google Scholar
• Tian W, Rojo de la Vega M, Schmidlin CJ, et al. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2). J Biol Chem. 2018;293(6):2029–2040.
   PubMed Web of Science ®Google Scholar
• Liu Z, Deng M, Wu L, et al. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. Mol Med. 2020;26(1):48.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23(22):8137–8151.
   PubMed Web of Science ®Google Scholar
• Bellezza I, Giambanco I, Minelli A, et al. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):721–733.
   PubMed Web of Science ®Google Scholar
• Katsuoka F, Otsuki A, Takahashi M, et al. Direct and specific functional evaluation of the Nrf2 and MafG Heterodimer by introducing a tethered dimer into small Maf-deficient cells. Mol Cell Biol. 2019;39(20):e00273–19.
   PubMed Web of Science ®Google Scholar
• Bartz RR, Piantadosi CA. Clinical review: oxygen as a signaling molecule. Crit Care. 2010;14(5):234.
   PubMed Web of Science ®Google Scholar
• Valavanidis A, Vlachogianni T, Fiotakis K, et al. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J Environ Res Public Health. 2013;10(9):3886–3907.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39(4):199–218.
   PubMed Web of Science ®Google Scholar
• Zang P, Qu WL, Yu YB, et al. Study on antioxidant effect of epigallocatechin gallate in food system. Sci Technol Food Industry. 2011;32(11):361–363.
   Google Scholar
• Wang J, Wang H, Sun K, et al. Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway. Drug Des Devel Ther. 2018;12:721–733.
   PubMed Web of Science ®Google Scholar
• Lee J, Kang JS, Nam LB, et al. Suppression of NRF2/ARE by convallatoxin sensitises A549 cells to 5-FU-mediated apoptosis. Free Radic Res. 2018;52(11–12):1416–1423.
   PubMed Web of Science ®Google Scholar
• Yan X, Qi M, Li P, et al. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell Biosci. 2017;7:50.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang X, Zhang Y, et al. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation. Sci Rep. 2017;7:39950.
   PubMed Web of Science ®Google Scholar
• Carlisi D, Buttitta G, Di Fiore R, et al. Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. Cell Death Dis. 2016;7(4):e2194.
   PubMedGoogle Scholar
• Chian S, Thapa R, Chi Z, et al. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun. 2014;447(4):602–608.
   PubMed Web of Science ®Google Scholar
• Furfaro AL, Traverso N, Domenicotti C, et al. The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev. 2016;2016:1958174.
   PubMed Web of Science ®Google Scholar
• Amiya E. Nrf-2: the target of vascular dysfunction in diabetes. Am J Hypertens. 2020;33(7):597–598.
   PubMed Web of Science ®Google Scholar
• Leonard MO, Kieran NE, Howell K, et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J. 2006;20(14):2624–2626.
   PubMed Web of Science ®Google Scholar
• Pedruzzi LM, Cardozo LF, Daleprane JB, et al. Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2. J Nephrol. 2015;28(4):495–501.
   PubMed Web of Science ®Google Scholar
• Liu M, Reddy NM, Higbee EM, et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int. 2014;85(1):134–141.
   PubMed Web of Science ®Google Scholar
• Li H, Cao YP, Zhang LS, et al. Tert-butylhydroquinone alleviates oxidative stress injury of glomerular mesangial cells induced by high glucose. Chin Pharmacol Bull. 2011;27(04):528–533.
   Google Scholar
• Spindel ON, World C, Berk BC. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal. 2012;16(6):587–596.
   PubMed Web of Science ®Google Scholar
• Hwang J, Suh HW, Jeon YH, et al. The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein. Nat Commun. 2014;5:2958.
   PubMed Web of Science ®Google Scholar
• Kim Y, Rouse M, González-Mariscal I, et al. Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of hepatic PI3K-AKT axis and IDE, and preservation of islet integrity. Nutr Metab (Lond). 2019;16:48.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492–2503.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30(2):251–262.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar Singh S, Kumar V, et al. Huntington’s disease: an update of therapeutic strategies. Gene. 2015;556(2):91–97.
   PubMed Web of Science ®Google Scholar
• Weigel D, Jürgens G, Küttner F, et al. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell. 1989;57(4):645–658.
   PubMed Web of Science ®Google Scholar
• Genin EC, Caron N, Vandenbosch R, et al. Concise review: forkhead pathway in the control of adult neurogenesis. Stem Cells. 2014;32(6):1398–1407.
   PubMed Web of Science ®Google Scholar
• Zhou B, Qian K, Hu MZ, et al. PI3K/Akt/FoxO3a/Bim signal pathway mediates the protective effect of hydrogen sulfide postconditioning on hypoxic H9c2 cardiomyocytes. Chin Pharmacol Bull. 2017;33(07):971–976.
   Google Scholar
• Tseng AH, Shieh SS, Wang DL. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med. 2013;63:222–234.
   PubMed Web of Science ®Google Scholar
• Coskun D, Obakan P, Arisan ED, et al. Epibrassinolide alters PI3K/MAPK signaling axis via activating Foxo3a-induced mitochondria-mediated apoptosis in colon cancer cells. Exp Cell Res. 2015;338(1):10–21.
   PubMed Web of Science ®Google Scholar
• Geng T, Li P, Yin X, et al. PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. Am J Pathol. 2011;178(4):1738–1748.
   PubMed Web of Science ®Google Scholar
• Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J. 2005;386(Pt 3):401–416.
   PubMedGoogle Scholar
• Ge QM, Bian F, Su Q. The role of NADPH oxidase in oxidative stress. Int J Endocrinol Metab. 2007;(06):395–398 + 402.
   Google Scholar
• Qin L, Liu Y, Hong JS, et al. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia. 2013;61(6):855–868.
   PubMed Web of Science ®Google Scholar
• Sanders LH, Timothy Greenamyre J. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med. 2013;62:111–120.
   PubMed Web of Science ®Google Scholar
• Sareila O, Kelkka T, Pizzolla A, et al. NOX2 complex-derived ROS as immune regulators. Antioxid Redox Signal. 2011;15(8):2197–2208.
   PubMed Web of Science ®Google Scholar
• Bao MH, Dai W, Li YJ, et al. Rutaecarpine prevents hypoxia-reoxygenation-induced myocardial cell apoptosis via inhibition of NADPH oxidases. Can J Physiol Pharmacol. 2011;89(3):177–186.
   PubMed Web of Science ®Google Scholar
• Lozhkin A, Vendrov AE, Pan H, et al. NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis. J Mol Cell Cardiol. 2017;102:10–21.
   PubMed Web of Science ®Google Scholar
• Quesada IM, Lucero A, Amaya C, et al. Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. Atherosclerosis. 2015;242(2):469–475.
   PubMed Web of Science ®Google Scholar
• Zhang F, Qian L, Flood PM, et al. Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther. 2010;333(3):822–833.
   PubMed Web of Science ®Google Scholar
• Jaquet V, Scapozza L, Clark RA, et al. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal. 2009;11(10):2535–2552.
   PubMed Web of Science ®Google Scholar
• Yang XL, Chen YJ, Hu GY, et al. Research progress of NADPH oxidases and their inhibitors. Yao Xue Xue Bao. 2016;51(4):499–506.
   PubMedGoogle Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–d1082.
   PubMed Web of Science ®Google Scholar
• Li XW, Hao W, Liu Y, et al. Effect of sequoyitol on expression of NOX4 and eNOS in aortas of type 2 diabetic rats. Yao Xue Xue Bao. 2014;49(3):329–336.
   PubMedGoogle Scholar
• Aoyama T, Paik YH, Watanabe S, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012;56(6):2316–2327.
   PubMed Web of Science ®Google Scholar
• Brandes RP, Weissmann N, Schröder K. Nox family NADPH oxidases: molecular mechanisms of activation. Free Radic Biol Med. 2014;76:208–226.
   PubMed Web of Science ®Google Scholar
• Zahradka P. Inhibition of NADPH oxidase by vaspin may prevent progression of atherosclerosis. Acta Physiol (Oxf). 2013;209(3):195–198.
   PubMed Web of Science ®Google Scholar
• Coffey ET. Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci. 2014;15(5):285–299.
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Deki-Arima N, Kaneko A, et al. Age-dependent motor dysfunction due to neuron-specific disruption of stress-activated protein kinase MKK7. Sci Rep. 2017;7(1):7348.
   PubMedGoogle Scholar
• Choi YJ, Kim HS, Lee J, et al. Down-regulation of oxidative stress and COX-2 and iNOS expressions by dimethyl lithospermate in aged rat kidney. Arch Pharm Res. 2014;37(8):1032–1038.
   PubMed Web of Science ®Google Scholar
• Santiago E, Martínez MP, Climent B, et al. Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2. Br J Pharmacol. 2016;173(22):3176–3195.
   PubMed Web of Science ®Google Scholar
• Mohammad H, Marchisella F, Ortega-Martinez S, et al. JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche. Mol Psychiatry. 2018;23(2):362–374.
   PubMed Web of Science ®Google Scholar
• Yarza R, Vela S, Solas M, et al. c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease. Front Pharmacol. 2015;6:321.
   PubMed Web of Science ®Google Scholar
• Zhao HB, Jiang YM, Li XJ, et al. Xiao Yao San improves the anxiety-like behaviors of rats induced by chronic immobilization stress: the involvement of the JNK signaling pathway in the Hippocampus. Biol Pharm Bull. 2017;40(2):187–194.
   PubMed Web of Science ®Google Scholar
• Suckfuell M, Lisowska G, Domka W, et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study. Otol Neurotol. 2014;35(8):1317–1326.
   PubMed Web of Science ®Google Scholar
• Suckfuell M, Canis M, Strieth S, et al. Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study. Acta Otolaryngol. 2007;127(9):938–942.
   PubMed Web of Science ®Google Scholar
• Hollos P, Marchisella F, Coffey ET. JNK regulation of depression and anxiety. Brain Plast. 2018;3(2):145–155.
   PubMedGoogle Scholar
• Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson’s diseases therapy. Curr Drug Targets CNS Neurol Disord. 2005;4(1):63–67.
   PubMedGoogle Scholar
• He W, Wang Y, Zhang MZ, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010;120(4):1056–1068.
   PubMed Web of Science ®Google Scholar
• Polak-Jonkisz D, Laszki-Szcząchor K, Rehan L, et al. Nephroprotective action of sirtuin 1 (SIRT1). J Physiol Biochem. 2013;69(4):957–961.
   PubMed Web of Science ®Google Scholar
• Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138–145.
   PubMed Web of Science ®Google Scholar
• Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond). 2013;124(3):153–164.
   PubMed Web of Science ®Google Scholar
• Xu Y, Nie L, Yin YG, et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol. 2012;259(3):395–401.
   PubMed Web of Science ®Google Scholar
• Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011;1812(7):719–731.
   PubMed Web of Science ®Google Scholar
• Kim MY, Lim JH, Youn HH, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. Diabetologia. 2013;56(1):204–217.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang Y, Ma X, et al. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep. 2012;39(9):9085–9093.
   PubMed Web of Science ®Google Scholar
• Artsi H, Cohen-Kfir E, Gurt I, et al. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology. 2014;155(9):3508–3515.
   PubMed Web of Science ®Google Scholar
• Minor RK, Baur JA, Gomes AP, et al. SRT1720 improves survival and healthspan of obese mice. Sci Rep. 2011;1:70.
   PubMed Web of Science ®Google Scholar
• Hou BY, Zhang L, Du GF. The role of Sirt1 in the injury of glomerular microvascular endothelial cells induced by high glucose. Chin J Pharmacol Toxicol. 2016;30(10):1051–1052.
   Google Scholar
• Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–158.
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhang Y, Zhuang L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12.
   PubMed Web of Science ®Google Scholar
• Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074.
   PubMed Web of Science ®Google Scholar
• Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593–602.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Valko M, Jomova K, Rhodes CJ, et al. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. Arch Toxicol. 2016;90(1):1–37.
   PubMed Web of Science ®Google Scholar
• Fan Z, Wirth AK, Chen D, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6(8):e371.
   PubMedGoogle Scholar
• Becerril-Ortega J, Bordji K, Fréret T, et al. Iron overload accelerates neuronal amyloid-β production and cognitive impairment in transgenic mice model of Alzheimer’s disease. Neurobiol Aging. 2014;35(10):2288–2301.
   PubMed Web of Science ®Google Scholar
• Everett J, Céspedes E, Shelford LR, et al. Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer’s disease peptide β-amyloid (1-42). J R Soc Interface. 2014;11(95):20140165.
   PubMed Web of Science ®Google Scholar
• Kang R, Kroemer G, Tang D. The tumor suppressor protein p53 and the ferroptosis network. Free Radic Biol Med. 2019;133:162–168.
   PubMed Web of Science ®Google Scholar
• Liu DS, Duong CP, Haupt S, et al. Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation . Nat Commun. 2017;8:14844.
   PubMed Web of Science ®Google Scholar
• Murphy MP. Metabolic control of ferroptosis in cancer. Nat Cell Biol. 2018;20(10):1104–1105.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181–1192.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Singh A, Domb AJ, et al. Therapeutic macromolecular iron chelators. Curr Med Chem. 2019;26(2):323–334.
   PubMed Web of Science ®Google Scholar
• Cosens DJ, Manning A. Abnormal electroretinogram from a Drosophila mutant. Nature. 1969;224(5216):285–287.
   PubMed Web of Science ®Google Scholar
• Kunert-Keil C, Bisping F, Krüger J, et al. Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains. BMC Genomics. 2006;7:159.
   PubMed Web of Science ®Google Scholar
• Yue Z, Xie J, Yu AS, et al. Role of TRP channels in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2015;308(3):H157–H182.
   PubMed Web of Science ®Google Scholar
• Kitajima N, Watanabe K, Morimoto S, et al. TRPC3-mediated Ca2+ influx contributes to Rac1-mediated production of reactive oxygen species in MLP-deficient mouse hearts. Biochem Biophys Res Commun. 2011;409(1):108–113.
   PubMed Web of Science ®Google Scholar
• Graham S, Ding M, Ding Y, et al. Canonical transient receptor potential 6 (TRPC6), a redox-regulated cation channel. J Biol Chem. 2010;285(30):23466–23476.
   PubMed Web of Science ®Google Scholar
• Shi J, Mori E, Mori Y, et al. Multiple regulation by calcium of murine homologues of transient receptor potential proteins TRPC6 and TRPC7 expressed in HEK293 cells. J Physiol. 2004;561(Pt 2):415–432.
   PubMed Web of Science ®Google Scholar
• Shimauchi T, Numaga-Tomita T, Ito T, et al. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight. 2017;2(15):1–17.
   Web of Science ®Google Scholar
• Nagakubo D, Taira T, Kitaura H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997;231(2):509–513.
   PubMed Web of Science ®Google Scholar
• Saito Y. DJ-1 as a biomarker of Parkinson’s disease. Adv Exp Med Biol. 2017;1037:149–171.
   PubMedGoogle Scholar
• Larsen K, Madsen LB, Høj A, et al. Porcine DJ-1: cloning of PARK7 cDNA, sequence comparison, expression analysis and chromosomal localization. Cytogenet Genome Res. 2007;116(1–2):93–99.
   PubMed Web of Science ®Google Scholar
• Junn E, Jang WH, Zhao X, et al. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res. 2009;87(1):123–129.
   PubMed Web of Science ®Google Scholar
• Martinat C, Shendelman S, Jonason A, et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol. 2004;2(11):e327.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu J, Chen S, et al. DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol. 2011;70(4):591–599.
   PubMed Web of Science ®Google Scholar
• Yu Y, Sun X, Gu J, et al. Deficiency of DJ-1 ameliorates liver fibrosis through inhibition of hepatic ROS production and inflammation. Int J Biol Sci. 2016;12(10):1225–1235.
   PubMed Web of Science ®Google Scholar
• Vasseur S, Afzal S, Tomasini R, et al. Consequences of DJ-1 upregulation following p53 loss and cell transformation. Oncogene. 2012;31(5):664–670.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu H, Chen L, et al. Park7 interacts with p47(phox) to direct NADPH oxidase-dependent ROS production and protect against sepsis. Cell Res. 2015;25(6):691–706.
   PubMed Web of Science ®Google Scholar
• Jiang L, Chen GB, Wang H, et al. MIP2 protects cardiomyocytes from oxidative stress injury through VDAC1 interaction. Chin J Pathophysiol. 2016;32(08):1521.
   Google Scholar
• Chang T, Untereiner A, Liu J, et al. Interaction of methylglyoxal and hydrogen sulfide in rat vascular smooth muscle cells. Antioxid Redox Signal. 2010;12(9):1093–1100.
   PubMed Web of Science ®Google Scholar
• Laggner H, Muellner MK, Schreier S, et al. Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic Res. 2007;41(7):741–747.
   PubMed Web of Science ®Google Scholar